Royal London Asset Management Reduces $36M in Merck & Co., Inc. ($MRK)

Royal London Asset Management has reduced its holdings in Merck & Co., Inc. (NYSE:MRK) by 300,997 shares, according to its latest 13F filing with the SEC. This adjustment decreases its stake by 9.4%, leaving it with 2,896,154 shares valued at approximately $344.8 million as of the reporting period ending March 31, 2026.

What Changed in Royal London Asset Management's Merck Position

Royal London Asset Management trimmed its Merck position from 3,197,151 shares to 2,896,154 shares, a reduction of 300,997 shares. This move represents a 9.4% decrease in their holdings, reflecting a strategic adjustment in their investment portfolio.

Other Institutional Activity in Merck

BlackRock, Inc. increased its Merck holdings by 6,734,865 shares, ending with 225,830,330 shares valued at about $27.2 billion. Vanguard Capital Management LLC added a significant stake, holding 160,987,624 shares worth roughly $19.4 billion. Meanwhile, State Street Corp reduced its position by 714,495 shares, holding 119,325,673 shares valued at $14.5 billion. Wellington Management Group LLP also trimmed its stake by 2,120,487 shares, now holding 84,314,971 shares valued at approximately $10.1 billion.

Merck Stock Snapshot

Shares of NYSE:MRK traded near $119.05 recently. Merck & Co., Inc. has a market capitalization of $294 billion and a P/E ratio of 33.5. The stock's 52-week range spans from $76.66 to $125.14, with a 50-day moving average of $116.18 and a 200-day moving average of $104.78. The company maintains a current ratio of 1.30, a quick ratio of 0.70, and a debt-to-equity ratio of 106.94.

Recent Earnings

Merck reported revenues of $65.8 billion, with a revenue growth of 4.9% over the previous year. The company's net margin stands at 13.6%, and it has a return on equity of 18.9%. Earnings per share were $3.55. Merck is scheduled to release its next earnings report on August 4, 2026.

Dividend

Merck offers an annual dividend rate of $3.40, providing a yield of 2.86%. The company's dividend payout ratio is 93.5%, indicating a strong commitment to returning value to shareholders.

Insider Buying and Selling at Merck & Co., Inc.

Several insiders, including Kathy Warden, Paul Rothman, Christine Seidman, Douglas Baker Jr., Patricia Russo, and Risa Lavizzo-Mourey, each purchased 1,853 shares of Merck stock at an average price of $118.72 on May 29, 2026. These transactions do not appear to be part of a pre-planned trading program.

Analysts Set New Price Targets

On May 1, 2026, Wells Fargo maintained its 'buy' rating on Merck with a price target of $145. UBS also kept a 'buy' rating with the same target on April 13, 2026. JP Morgan maintained a 'buy' rating with a $135 target on April 6, 2026. Citigroup held its 'hold' rating with a target of $125 on March 20, 2026. The consensus among 27 analysts is a 'buy' rating, with a mean price target of $129.74.

About Merck & Co., Inc.

Merck & Co., Inc. is a global healthcare company based in Rahway, New Jersey. It develops and provides pharmaceuticals, vaccines, and health solutions for both human and animal health. The company is led by CEO Robert M. Davis and employs approximately 73,000 people. Merck's products cover a wide range of therapeutic areas and include well-known brands like Keytruda, Gardasil, and Januvia.

Bottom Line

Royal London Asset Management's recent reduction in its Merck holdings reflects a strategic portfolio adjustment. Investors often track these filings for insight into the fund's investment decisions, though it's important to remember that 13F filings are backward-looking and may not represent the current position. Merck continues to be a strong player in the healthcare sector, with ongoing analyst support and a solid dividend offering.